Literature DB >> 12161353

Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.

Roberta La Starza1, Maurizio Trubia, Nicoletta Testoni, Emanuela Ottaviani, Elena Belloni, Barbara Crescenzi, Massimo Martelli, Georges Flandrin, Pier Giuseppe Pelicci, Cristina Mecucci.   

Abstract

BACKGROUND AND OBJECTIVES: The ETV6 gene undergoes rearrangements with tyrosine kinases in hematologic malignancies and solid tumors. ETV6/ABL1 chimeric proteins have been detected both in lymphoid and myeloid disorders. Our objective was to study two new cases of ETV6/ABL1-positive acute myeloid leukemia (AML) and to focus on bone marrow morphology and on molecular cytogenetics of eosinophilic cells. DESIGN AND METHODS: Fluorescence in situ hybridization (FISH) was performed in two AML cases with different translocations, i.e. t(8;12)(p21;p13) and t(9;12) (q34; p13). We used probes for the short arm of chromosome 12, for ABL1 and BCR, for centromeric regions, and for whole chromosome arms. Polymerase chain reaction (PCR) was carried out by applying primers selected for the ETV6 gene.
RESULTS: In both cases, bone marrow morphology was characterized by trilineage dysplasia and increased abnormal eosinophils. FISH showed the 5'ETV6 translocated to chromosome 8 in patient #1, and to chromosome 9 in patient #2. A 3' PCR identified chimeric products resulting from fusion between ETV6 exon 4 or exon 5, and ABL1 exon 2. Accordingly, an ETV6/ABL1 fusion signal was detected on der(8) in patient #1, and on der(9) in patient #2. Using interphase FISH abnormal bone marrow eosinophils were proved to belong to the neoplastic clone, carrying the ETV6 rearrangement. INTERPRETATION AND
CONCLUSIONS: Our findings provide new information on the heterogeneity of conventional cytogenetics in ETV6/ABL1 positive leukemias, and indicate the putative target cell in this AML is an immature precursor capable of terminally differentiating towards eosinophils.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161353

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

2.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

3.  Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.

Authors:  Katya Gancheva; Andres Virchis; Julie Howard-Reeves; Nick Cp Cross; Diana Brazma; Colin Grace; Paul Kotzampaltiris; Fedra Partheniou; Elisabeth Nacheva
Journal:  Mol Cytogenet       Date:  2013-09-20       Impact factor: 2.009

4.  An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.

Authors:  Purvi M Kakadia; Ralf Schmidmaier; Andreas Völkl; Irene Schneider; Natalia Huk; Stephanie Schneider; Gerda Panzner; Ulrike Neidel; Barbara Fritz; Karsten Spiekermann; Stefan K Bohlander
Journal:  Leuk Res Rep       Date:  2016-10-14

5.  A Case of Chronic Myeloid Leukemia With Rare Variant ETV6/ABL1 Rearrangement.

Authors:  Soo In Choi; Mi Ae Jang; Woo Joon Jeong; Byung Ryul Jeon; Yong Wha Lee; Hee Bong Shin; Dae Sik Hong; You Kyoung Lee
Journal:  Ann Lab Med       Date:  2017-01       Impact factor: 3.464

Review 6.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

7.  A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature.

Authors:  Carlos A Tirado; Ken Siangchin; David S Shabsovich; Maryam Sharifian; Gary Schiller
Journal:  Biomark Res       Date:  2016-08-25

8.  [Acute myeloid leukemia with co-expression of TEL-ABL1 and NUP98-HOXA9 fusion genes: a case report and literature review].

Authors:  C Y Wu; Y L Li; X Y Dong; L Zhang; B J Shang; W Li; Z B Li; L Zhang; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-07-14

9.  Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.

Authors:  JinJuan Yao; Lianrong Xu; Umut Aypar; Howard J Meyerson; Dory Londono; Qi Gao; Jeeyeon Baik; James Dietz; Ryma Benayed; Allison Sigler; Mariko Yabe; Ahmet Dogan; Maria E Arcila; Mikhail Roshal; Yanming Zhang; Michael J Mauro; Wenbin Xiao
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.